Literature DB >> 19622043

A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients.

Ronen Ben-Ami1, Jesús Rodríguez-Baño, Hande Arslan, Johann D D Pitout, Claudine Quentin, Esther S Calbo, Ozlem K Azap, Corinne Arpin, Alvaro Pascual, David M Livermore, Javier Garau, Yehuda Carmeli.   

Abstract

BACKGROUND: Infections caused by extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae are increasing in frequency and are associated with high mortality rates. Circulation of CTX-M-type ESBLs in the community is of particular concern, because it may confound standard infection-control measures.
METHODS: We analyzed the results of epidemiologic studies of infection caused by ESBL-producing Enterobacteriaceae in nonhospitalized patients from 6 centers in Europe, Asia, and North America. Risk factors for infection with an ESBL-producing organism were identified by univariate and multivariate analyses.
RESULTS: A total of 983 patient-specific isolates were reviewed (890 [90.5%] of which were Escherichia coli, 68 [6.9%] of which were Klebsiella species, and 25 [2.5%] of which were Proteus mirabilis); 339 [34.5%] of the isolates produced ESBLs. CTX-M types were the most frequent ESBLs (accounting for 65%). Rates of co-resistance to ciprofloxacin among ESBL-producing isolates were high (>70%), but significant variation was seen among centers with respect to rates of resistance to gentamicin, amoxicillin-clavulanate, and trimethoprim-sulfamethoxazole. Similar risk factors for infection with an ESBL-producing organism were found in the different participating centers. Significant risk factors, identified by multivariate analysis, were recent antibiotic use, residence in a long-term care facility, recent hospitalization, age 65 years, and male sex (area under the receiver-operator characteristic [ROC] curve, 0.80). However, 34% of ESBL-producing isolates (115 of 336 isolates) were obtained from patients with no recent health care contact; the area under the ROC curve for the multivariate model for this group of patients was only 0.70, which indicated poorer predictive value.
CONCLUSIONS: Community-acquired ESBL-producing Enterobacteriaceae are now prevalent worldwide, necessitating international collaboration. Novel approaches are required to adequately address issues such as empirical treatment for severe community-acquired infection and infection control.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19622043     DOI: 10.1086/604713

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  148 in total

1.  Epidemiology and risk factors of community onset infections caused by extended-spectrum β-lactamase-producing Escherichia coli strains.

Authors:  Cheol-In Kang; Yu Mi Wi; Mi Young Lee; Kwan Soo Ko; Doo Ryeon Chung; Kyong Ran Peck; Nam Yong Lee; Jae-Hoon Song
Journal:  J Clin Microbiol       Date:  2011-12-07       Impact factor: 5.948

2.  The association between antibiotic use and resistance: the role of secondary antibiotics.

Authors:  J A Bosso; P D Mauldin; C D Salgado
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-06-10       Impact factor: 3.267

Review 3.  Preventing the spread of multidrug-resistant gram-negative pathogens: recommendations of an expert panel of the German Society For Hygiene and Microbiology.

Authors:  Frauke Mattner; Franz-C Bange; Elisabeth Meyer; Harald Seifert; Thomas A Wichelhaus; Iris F Chaberny
Journal:  Dtsch Arztebl Int       Date:  2012-01-20       Impact factor: 5.594

4.  Antimicrobial management of intra-abdominal infections: literature's guidelines.

Authors:  Massimo Sartelli; Fausto Catena; Federico Coccolini; Antonio Daniele Pinna
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

5.  Differential characteristics of healthcare-associated compared to community-acquired febrile urinary tract infections in males.

Authors:  A Smithson; J Ramos; M T Bastida; S Bernal; N Jove; E Niño; N Msabri; R Porrón
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-09-25       Impact factor: 3.267

6.  Identifying patients harboring extended-spectrum-beta-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system.

Authors:  Mario Tumbarello; Enrico Maria Trecarichi; Matteo Bassetti; Francesco Giuseppe De Rosa; Teresa Spanu; Eugenia Di Meco; Angela Raffaella Losito; Andrea Parisini; Nicole Pagani; Roberto Cauda
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

Review 7.  Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa.

Authors:  Souha S Kanj; Zeina A Kanafani
Journal:  Mayo Clin Proc       Date:  2011-03       Impact factor: 7.616

8.  Impact of Gram-negative bacteria on the treatment of venous leg ulcers.

Authors:  Wibke L Engelberg; Martin Dörler; Markus Stücker; Stefanie Reich-Schupke
Journal:  Int Wound J       Date:  2018-08-05       Impact factor: 3.315

9.  Community-onset Escherichia coli infection resistant to expanded-spectrum cephalosporins in low-prevalence countries.

Authors:  Benjamin A Rogers; Paul R Ingram; Naomi Runnegar; Matthew C Pitman; Joshua T Freeman; Eugene Athan; Sally M Havers; Hanna E Sidjabat; Mark Jones; Earleen Gunning; Mary De Almeida; Kaylene Styles; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2014-01-27       Impact factor: 5.191

10.  Appropriateness of empirical treatment and outcome in bacteremia caused by extended-spectrum-β-lactamase-producing bacteria.

Authors:  Florine N J Frakking; Wouter C Rottier; J Wendelien Dorigo-Zetsma; Jarne M van Hattem; Babette C van Hees; Jan A J W Kluytmans; Suzanne P M Lutgens; Jan M Prins; Steven F T Thijsen; Annelies Verbon; Bart J M Vlaminckx; James W Cohen Stuart; Maurine A Leverstein-van Hall; Marc J M Bonten
Journal:  Antimicrob Agents Chemother       Date:  2013-04-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.